Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. Piris
Kir3dl2 Mutation May Define a High Rate of Response of Aitl to Tipifarnib
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Stochastic Activation of a DNA Damage Response Causes Cell-To-Cell Mutation Rate Variation
Science
Multidisciplinary
Philosophy of Science
History
Kir3dl2 Is Expressed in Peripheral T-Cell Lymphomas and May Be a Therapeutic Target
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (Aitl) and Cxcl12+ Peripheral T-Cell Lymphoma (Ptcl): Preliminary Results From a Phase 2 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Evidence for a High Mutation Rate at Rapidly Evolving Yeast Centromeres
BMC Evolutionary Biology
Evolution
Ecology
Systematics
Behavior
Pharmacotherapy of Hematologic Malignancies With Tipifarnib
Clinical Medicine. Therapeutics
Loss of HAX-1 May Contribute to the Neurodegeneration Caused by a Kv3.3 Mutation
Biophysical Journal
Biophysics
Random Forest Segregation of Drug Responses May Define Regions of Biological Significance
Frontiers in Computational Neuroscience
Neuroscience
Cellular
Molecular Neuroscience
Somatic Mutation of DNAH Genes Implicated Higher Chemotherapy Response Rate in Gastric Adenocarcinoma Patients
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
High Th17:Treg Ratio May Predict Complete Response to HDIL-2 in the Setting of Melanoma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology